Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG RHHBY supplemental marketing application for Evrysdi (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). 

  • Evrysdi is already approved to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
  • The submission incorporates interim data from the RAINBOWFISH study.
  • The data showed that most pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking, and maintaining the ability to swallow following 12 months of treatment.
  • No treatment-related serious adverse events were reported in any babies treated with Evrysdi through the interim safety analysis period (n=12).
  • The latest results from the RAINBOWFISH study will be presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March 2022.
  • Price Action: RHHBY shares are down 1.59% at $47.04 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!